Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL679843 | 0.86 | PLCG1 (0.32) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL679840 | 0.85 | PLCG1 (0.31) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL679539 | 0.84 | ATM (0.32) | PLCG1 | |
| SCHEMBL679168 | 0.81 | PLCG1 (0.30) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL679490 | 0.79 | — | — | |
| SCHEMBL678135 | 0.79 | PLCG1 (0.31) | PLCG1 | |
| SCHEMBL2928562 | 0.76 | PLCG1 (0.34) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL3555646 | 0.76 | NPC1 (0.33) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL3546268 | 0.76 | POLB (0.32) | PLCG1POLBSMN1; SMN2 | |
| SCHEMBL3555648 | 0.75 | PLCG1 (0.33) | PLCG1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288063-A1 | NOVEL FUSED BRIDGED BICYCLIC HETEROARYL SUBSTITUTED 6-ALKYLIDENE PENEMS AS POTENT BETA-LACTAMASE INHIBITORS | B2M, MRPL21, RCE1 | PLCG1 4264/4885POLB 724/4885SMN1; SMN2 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.